Syncona’s largest-ever series A commitment goes to CNS gene therapy play SwanBio

SwanBio has expanded its series A round to $77 million to scale up manufacturing for its neurodegenerative gene therapies and drive its lead program toward clinical testing.

SwanBio Therapeutics Ltd. Thursday added $52 million in series A financing, of which $51 million came from majority shareholder Syncona Ltd. (LSE:SYNC), with the other $1 million coming from Partners Innovation Fund. Syncona Chief Investment Officer Chris Hollowood told BioCentury the firm’s commitment includes $19.6 million now, with the rest to come via milestone-driven tranches. ...